Camizestrant vs Giredestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Camizestrant · Etcamah

Marketed by AstraZeneca

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT04964934 · Phase 3 · active, not recruiting

This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT04644068 (registry estimate)

Reported efficacy

Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)

Result source: NCT04964934

Giredestrant

Marketed by Roche

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT04546009 · Phase 3 · active, not recruiting

This was a large (n=992), randomized, double-blind, active-controlled phase 3 trial using progression-free survival, a hard clinical endpoint, as its primary measure -- a strong design overall. However, the reported result showed only a numerical trend favoring giredestrant that did not reach statistical significance, so the trial does not provide confirmed evidence of benefit despite its rigorous design.

Next expected readout: July 2027 · NCT03332797 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1 (From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)): persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. (missed)

Result source: NCT04546009

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCamizestrantGiredestrant
PFS, median—Trial running · NCT07717450—Trial running · NCT06065748
OS, median—Trial running · NCT07717450—Trial running · NCT06065748
ORR—Trial running · NCT07717450—Trial running · NCT06065748
Clinical benefit rate—Trial running · NCT07717450—Trial running · NCT06065748

PFS, median

Camizestrant
—Trial running · NCT07717450
Giredestrant
—Trial running · NCT06065748

OS, median

Camizestrant
—Trial running · NCT07717450
Giredestrant
—Trial running · NCT06065748

ORR

Camizestrant
—Trial running · NCT07717450
Giredestrant
—Trial running · NCT06065748

Clinical benefit rate

Camizestrant
—Trial running · NCT07717450
Giredestrant
—Trial running · NCT06065748
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Camizestrant
SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 NCT04964934 · Phase 3 · design grade: strong · publication or press release
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) NCT04588298 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Camizestrant: 4 of 4 rows · Giredestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamizestrantGiredestrant
Dropout rate
3.3%75 mga
NCT04588298 · Phase 2
show 4 more results
3.3%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
8.7%a
NCT05659563 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
—a
NCT05659563 · Phase 2 · registry result, not featured evidence
Serious AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
0%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
0%a
NCT05659563 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
75 mga
nausea 13.3%
fatigue 6.7%
headache 6.7%
NCT04588298 · Phase 2
show 4 more results
75 mg
visual impairment 20%
headache 10%
photopsia 10%
NCT04588298 · Phase 2
300 mg
hypertension 23.1%
visual impairment 23.1%
photopsia 15.4%
NCT04588298 · Phase 2
150 mg
visual impairment 15.2%
diplopia 12.1%
photopsia 12.1%
NCT04588298 · Phase 2
150 mg
visual impairment 24.1%
diplopia 17.2%
hypertension 13.8%
NCT04588298 · Phase 2
a
arthralgia 9.5%
hot flush 9.5%
fatigue 7.1%
NCT05659563 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Giredestrant

Ki67 -14.5% (n=40) vs -10% (n=44) Tamoxifen @ 2.14wk
absolute change · percentage points
NCT05659563 · Phase 2 · registry result, not featured evidence
Complete Cell Cycle Arrest 17.5% (n=40) vs 4.5% (n=44) Tamoxifen @ 2.14wk
absolute value · percentage points
NCT05659563 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camizestrant's landscape · Giredestrant's landscape